Doctor profile · Federal record
Dr. PATRICK BEHNKE, NP
Adult Health Nurse Practitioner (CMS: NURSE PRACTITIONER) · CHESTERFIELD, MO
- NPI 1417490772
- Accepts Medicare
- 10 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
100 CHESTERFIELD BUSINESS PKWY STE 110
CHESTERFIELD, MO 630051271
(636) 532-0990
fax (636) 532-0993
Credentials & registration
- NPI registered
- November 2016 — 10 yrs on file
- Profile last updated
- October 21, 2025
- Year of graduation
- 2016 — 10 yrs since
- Specialty taxonomy
- 363LA2200X — NUCC code
- State license (1)
- Missouri #2016041026
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1417490772. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
161
Distinct HCPCS
5
Medicare allowed
$7,401
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 60 | 17 | $6 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 42 | 41 | $75 | |
17110 |
Destruction of skin growth, 1-14 growths | 24 | 24 | $94 | |
17000 |
Destruction of precancer skin growth, 1 growth | 22 | 21 | $37 | |
11102 |
Biopsy of related skin growth, first growth | 13 | 13 | $68 |
In context: peer comparison
Among 13 peers in this city , average services per provider: 118. This provider delivers 1.4× the peer median.Open Payments
Industry payments received
All-time total
$7,481
Transactions
255
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| UCB, Inc. | 12 | $2,151.56 | |
| Lilly USA, LLC | 13 | $1,529.26 | |
| ABBVIE INC. | 64 | $937.92 | |
| Janssen Biotech, Inc. | 20 | $496.24 | |
| E.R. Squibb & Sons, L.L.C. | 25 | $361.99 | |
| Novartis Pharmaceuticals Corporation | 22 | $259.40 | |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 8 | $253.85 | |
| PFIZER INC. | 20 | $236.43 | |
| Arcutis Biotherapeutics, Inc. | 19 | $216.15 | |
| Dermavant Sciences, Inc. | 22 | $200.03 | |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 8 | $195.64 | |
| Incyte Corporation | 8 | $172.33 | |
| Amgen Inc. | 5 | $101.97 | |
| Galderma Laboratories, L.P. | 5 | $99.17 | |
| Regeneron Healthcare Solutions, Inc. | 4 | $89.05 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
372
Patients
186
Total drug cost
$424,108
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Ketoconazole | Generic | 85 | 48 | $1,218 |
| Clobetasol Propionate | Generic | 66 | 34 | $3,784 |
| Triamcinolone Acetonide | Generic | 59 | 46 | $883 |
| Fluorouracil | Generic | 36 | 34 | $3,404 |
| Hydroxyzine Hcl | Generic | 29 | 0 | $282 |
| Taltz Autoinjector (Ixekizumab) | Brand | 23 | 0 | $153,901 |
| Doxycycline Hyclate | Generic | 22 | 11 | $1,618 |
| Terbinafine Hcl | Generic | 17 | 13 | $57 |
| Metronidazole | Generic | 12 | 0 | $553 |
| Skyrizi Pen (Risankizumab-Rzaa) | Brand | 12 | 0 | $258,166 |